铂敏感复发性卵巢癌手术治疗的研究进展  

Progress of Surgery on Platinum-sensitive Recurrent Ovarian Cancer

作　　者：何丽雅 陈雅卿 HE Liya;CHEN Yaqing(Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,China;Department of Gynaecologic Oncology,Cancer Hospital of The University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Institute of Cancer and Basic Medicine(IBMC),Chinese Academy of Sciences,Hangzhou 310022,China)

机构地区：[1]浙江中医药大学第二临床医学院,杭州310053 [2]中国科学院大学附属肿瘤医院(浙江省肿瘤医院)妇瘤外科,中国科学院肿瘤与基础医学研究所,杭州310022

出　　处：《肿瘤防治研究》2021年第9期903-906,共4页Cancer Research on Prevention and Treatment

摘　　要：复发性卵巢癌的高发率及致死率一直是临床上的难题。对部分铂类敏感的复发性卵巢癌患者,采用二次肿瘤细胞减灭术(SCS)及以铂类为基础的后续联合化疗可以延长生存时间,改善生活质量。因此,正确识别可以受益于手术治疗的患者是关键问题。目前已有研究提出一些预测模型来选择适合SCS的患者。本文就近年来对铂敏感复发性卵巢癌手术治疗的研究进展进行综述。The high incidence and fatality rate of recurrent ovarian cancer(ROC)have always been the clinical problem.For part of patients with platinum-sensitive recurrent ovarian cancer,the secondary cytoreductive surgery(SCS)followed by platinum-based combination chemotherapy can prolong their survival time and improve quality of life.Therefore,it’s a critical matter to accurately identify the patients who will benefit from surgery treatment.Several predictive models have been proposed for the selection of the patients for SCS.This article summarizes the research progress in the surgical treatment of platinum-sensitive recurrent ovarian cancer in recent years.

关 键 词：复发性卵巢癌 二次肿瘤细胞减灭术 铂敏感 

分 类 号：R737.31[医药卫生—肿瘤]